Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Methicillin-Resistant Staphylococcus Aureus | Pharmacor | G7 | 2014

Login to access report north_east
Contact sales account_box

Methicillin-resistant Staphylococcus aureus (MRSA) is an important causative pathogen of a range of hospital-treated infections. The steadily increasing severity of infections caused by MRSA that require hospital treatment and the decreasing susceptibility of this pathogen to current antibiotics continue to drive the need for novel therapies. The success of two agents—linezolid (Pfizer’s Zyvox/Zyvoxid) and daptomycin (Cubist/Novartis/Merck’s Cubicin)—has demonstrated the commercial potential that can be achieved in this market and has contributed to continued interest in drug development for novel antibiotics active against MRSA. With up to eight new emerging therapies set to launch by 2022, the competition within the hospital-treated MRSA (HT-MRSA) market will intensify as a growing number of therapies compete for limited patient share. Therefore, new emerging therapies will find uptake in segments of the HT-MRSA market with high unmet need, helping sustain the market even as key branded agents lose patent protection.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east